Search Page

1

Cite

Share

Severe cutaneous adverse reactions to drugs.

Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Duong TA, et al. Among authors: wolkenstein p. Lancet. 2017 Oct 28;390(10106):1996-2011. doi: 10.1016/S0140-6736(16)30378-6. Epub 2017 May 2. Lancet. 2017. PMID: 28476287 Review.

Cite

Share

2

Cite

Share

Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.

Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, Blakeley J, Babovic-Vuksanovic D, Cunha KS, Ferner R, Fisher MJ, Friedman JM, Gutmann DH, Kehrer-Sawatzki H, Korf BR, Mautner VF, Peltonen S, Rauen KA, Riccardi V, Schorry E, Stemmer-Rachamimov A, Stevenson DA, Tadini G, Ullrich NJ, Viskochil D, Wimmer K, Yohay K; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC), Huson SM, Evans DG, Plotkin SR. Legius E, et al. Among authors: wolkenstein p. Genet Med. 2021 Aug;23(8):1506-1513. doi: 10.1038/s41436-021-01170-5. Epub 2021 May 19. Genet Med. 2021. PMID: 34012067 Free PMC article.

Cite

Share

3

Cite

Share

NF1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: the French experience.

Sabbagh A, Pasmant E, Imbard A, Luscan A, Soares M, Blanché H, Laurendeau I, Ferkal S, Vidaud M, Pinson S, Bellanné-Chantelot C, Vidaud D, Parfait B, Wolkenstein P. Sabbagh A, et al. Among authors: wolkenstein p. Hum Mutat. 2013 Nov;34(11):1510-8. doi: 10.1002/humu.22392. Epub 2013 Aug 26. Hum Mutat. 2013. PMID: 23913538

Cite

Share

4

Cite

Share

Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells.

Radomska KJ, Coulpier F, Gresset A, Schmitt A, Debbiche A, Lemoine S, Wolkenstein P, Vallat JM, Charnay P, Topilko P. Radomska KJ, et al. Among authors: wolkenstein p. Cancer Discov. 2019 Jan;9(1):130-147. doi: 10.1158/2159-8290.CD-18-0156. Epub 2018 Oct 22. Cancer Discov. 2019. PMID: 30348676

Cite

Share

5

Cite

Share

Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966.

Bergqvist C, Servy A, Valeyrie-Allanore L, Ferkal S, Combemale P, Wolkenstein P; NF France Network. Bergqvist C, et al. Among authors: wolkenstein p. Orphanet J Rare Dis. 2020 Feb 3;15(1):37. doi: 10.1186/s13023-020-1310-3. Orphanet J Rare Dis. 2020. PMID: 32014052 Free PMC article.

Cite

Share

6

Cite

Share

SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.

Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. Bastuji-Garin S, et al. Among authors: wolkenstein p. J Invest Dermatol. 2000 Aug;115(2):149-53. doi: 10.1046/j.1523-1747.2000.00061.x. J Invest Dermatol. 2000. PMID: 10951229 Free article.

Cite

Share

7

Cite

Share

Acne prevalence and associations with lifestyle: a cross-sectional online survey of adolescents/young adults in 7 European countries.

Wolkenstein P, Machovcová A, Szepietowski JC, Tennstedt D, Veraldi S, Delarue A. Wolkenstein P, et al. J Eur Acad Dermatol Venereol. 2018 Feb;32(2):298-306. doi: 10.1111/jdv.14475. Epub 2017 Sep 6. J Eur Acad Dermatol Venereol. 2018. PMID: 28707712 Free article.

Cite

Share

8

Cite

Share

[Phacomatosis].

Valeyrie-Allanore L, Wolkenstein P. Valeyrie-Allanore L, et al. Among authors: wolkenstein p. Rev Prat. 2008 Apr 15;58(7):717-24. Rev Prat. 2008. PMID: 18546640 Review. French.

Cite

Share

9

Cite

Share

[Disulone].

Begon E, Chosidow O, Wolkenstein P. Begon E, et al. Among authors: wolkenstein p. Ann Dermatol Venereol. 2004 Dec;131(12):1062-73. doi: 10.1016/s0151-9638(04)93842-2. Ann Dermatol Venereol. 2004. PMID: 15692440 Review. French.

Cite

Share

10

Cite

Share

MEK inhibitors in RASopathies.

Bergqvist C, Wolkenstein P. Bergqvist C, et al. Among authors: wolkenstein p. Curr Opin Oncol. 2021 Mar 1;33(2):110-119. doi: 10.1097/CCO.0000000000000711. Curr Opin Oncol. 2021. PMID: 33395032 Review.

Cite

Share